Non-Small Cell Lung Cancer Therapy: Biomarkers Meet Cell Therapy

Introduction: A New Era for Non-Small Cell Lung Cancer Therapy

Non-small cell lung cancer (NSCLC) accounts for roughly 77% to 87% of all lung cancer diagnoses, depending on the source. According to the American Cancer Society’s Cancer Statistics, 2026 and SEER data from the National Cancer Institute, lung and bronchus cancer is projected to cause 229,410 new cases and 124,990 deaths in the United States in 2026. It remains the leading cause of cancer death for both men and women.

Survival figures show why urgency persists. The overall 5-year relative survival rate for lung cancer is 28%, but that number hides a wide gap: survival is roughly 65% for localized disease and only 10% for distant-stage (metastatic) disease.

There is also real progress. Five-year survival for distant-stage lung cancer has risen from 2% to 10% over time, a gain largely credited to targeted therapy and immunotherapy.

This guide is organized differently from most NSCLC overviews, which typically group treatment by modality (surgery, chemotherapy, radiation). This article instead organizes treatment by biomarker, matching each actionable mutation to its approved therapy. It then looks beyond current standard of care to the emerging cell-and-gene therapy frontier, including CAR-T, tumor-infiltrating lymphocyte (TIL) therapy, and mRNA neoantigen vaccines, which are now entering NSCLC research.

This article is written for a general audience as an informational guide. It is not a substitute for personalized medical advice, and readers should discuss any treatment questions with a qualified healthcare provider.

Why Biomarker Testing Comes Before Treatment Decisions

Precision oncology is now the standard of care. Both NCCN and ASCO guidelines recommend comprehensive next-generation sequencing (NGS)-based testing before systemic therapy begins for advanced NSCLC. These panels cover the key actionable genes:

• EGFR
• ALK
• ROS1
• BRAF
• KRAS
• MET
• RET
• NTRK
• HER2 (ERBB2)

PD-L1 testing is added to this panel because it helps guide immunotherapy decisions.

NGS panels test many genes at once from a single sample. This approach is broader and often faster than testing one gene at a time, and it saves tissue that might otherwise run out. Liquid biopsy, which looks for tumor DNA in a blood sample, offers a less invasive option. It is especially useful when tissue is limited or a repeat biopsy is difficult.

The practical result is significant: in advanced NSCLC, biomarker status, and not stage alone, now determines first-line treatment.

Testing should also not be skipped based on assumptions about who “typically” has a mutation. In NSCLC cohorts, KRAS is the most common actionable driver (about 27%, with G12C the largest subgroup), followed by EGFR (about 17%). EGFR mutations are more common in never-smokers and women, while KRAS is more frequent in smokers. Even so, both appear across all demographic groups, which is why comprehensive testing is recommended for every eligible patient.

The Biomarker-to-Therapy Map: 2026’s Actionable Mutations in NSCLC

This section is the core of the guide. It walks through each actionable mutation and the approved targeted agents that match it, reflecting the most current 2026 approvals. Because therapy is chosen based on the specific molecular driver in a patient’s tumor, this map reflects how treatment decisions are actually made in modern lung cancer care.

EGFR Mutations

EGFR exon 19 deletions and the L858R point mutation are the most common EGFR alterations driving NSCLC, particularly among never-smokers.

According to the 2026 NCCN Guidelines for Patients, preferred first-line options for EGFR exon 19 deletion or L858R-positive metastatic NSCLC include:

• Osimertinib, alone or combined with carboplatin and pemetrexed chemotherapy
• Lazertinib plus amivantamab-vmjw

Data from the FLAURA2 trial show the benefit of combination approaches. Osimertinib plus chemotherapy achieved a median overall survival of 47.5 months, compared with 37.6 months for osimertinib alone.

When the disease progresses, datopotamab deruxtecan (Datroway), an antibody-drug conjugate (ADC), is approved for EGFR-mutated NSCLC after prior TKI therapy and chemotherapy.

Research is also continuing on less common EGFR subtypes. Zipalertinib, which targets EGFR exon 20 insertions, has a New Drug Application (NDA) accepted by regulators. This reflects ongoing efforts to tailor therapy to specific EGFR variants.

ALK Rearrangements

ALK-positive NSCLC is a distinct, targetable subtype. It is typically seen in younger patients, many of whom have never smoked.

A landmark development in 2026 is the approval of adjuvant alectinib for resected ALK-positive NSCLC, the first molecularly targeted adjuvant therapy approved specifically for this subtype. Its clinical impact includes strong protection of the brain: intracranial progression occurred in 11% of patients on alectinib versus 46% on chemotherapy.

The next wave is already in development. Neladalkib, a fourth-generation, brain-penetrant ALK tyrosine kinase inhibitor (TKI), has a submitted NDA.

ROS1 Rearrangements

ROS1 fusions are rarer, but they are a well-established actionable target. They are mechanistically related to ALK, and some drugs act on both.

In July 2026, zidesamtinib (Jideytro) was approved for ROS1-positive NSCLC in patients previously treated with a ROS1 TKI. This approval addresses acquired resistance, which occurs when tumors adapt to an initial targeted drug.

Zidesamtinib is part of a broader trend in NSCLC. Instead of relying on a single drug for the entire course of treatment, care increasingly uses sequential, resistance-targeting TKIs designed for each stage of the disease.

HER2 Alterations

HER2 (ERBB2) mutations were historically an underserved biomarker in NSCLC. Several recent approvals have changed that.

• Zongertinib: Originally granted accelerated approval in August 2025 for previously treated patients, its indication was expanded in February 2026 to include first-line treatment of HER2-mutant NSCLC.
• Sevabertinib (Hyrnuo): Granted accelerated approval in September 2026 for first-line treatment of treatment-naive HER2-mutant NSCLC, based on data from the SOHO-01 trial. Clinicians now have a second first-line HER2 option.
• Trastuzumab deruxtecan: The established ADC option for HER2-altered metastatic NSCLC, covering treatment across multiple lines of therapy.

MET Alterations (Exon 14 Skipping and Overexpression)

Two related but distinct MET categories matter in NSCLC:

1. MET exon 14 skipping mutations, a genetic alteration detected through molecular testing
2. c-MET protein overexpression, detected by measuring protein levels in tumor tissue

For c-MET overexpressing metastatic NSCLC, telisotuzumab vedotin-tllv (Emrelis) is an approved antibody-drug conjugate. MET-targeted therapy shows how ADCs, which deliver a cancer-killing payload directly to cells carrying a specific marker, are expanding options beyond traditional small-molecule TKIs.

RET Rearrangements

RET fusions are less common, but they are clinically important. Selective RET inhibitors are established standard options, and researchers continue to refine how RET-targeted therapy is sequenced. This work is part of a broader wave of progress: 2025 was described in the medical literature as “a remarkable year” for NSCLC, with seven new FDA approvals across molecular targets, including ADCs, bispecific antibodies, and TKIs.

KRAS Mutations

KRAS is the most frequently identified actionable driver in NSCLC (about 27%). G12C is the largest subgroup, and the mutation is more common in smokers.

For decades, KRAS was considered “undruggable.” KRAS G12C-directed therapies have since become an established treatment pathway. Innovation is now moving past G12C-selective agents. Daraxonrasib has entered the NCCN emerging-biomarker framework for KRAS-mutant NSCLC, suggesting that broader KRAS targeting may be on the horizon.

NTRK Gene Fusions

NTRK fusions are rare in NSCLC, but they are a tumor-agnostic biomarker found across many cancer types. NTRK inhibitors are approved based on the presence of the mutation itself rather than the organ where the cancer started. This model points to where oncology is heading more broadly: treatment defined by molecular biology rather than tumor location.

Driver-Negative NSCLC: Where Immunotherapy Remains the Backbone

A substantial share of patients with advanced NSCLC have no identifiable actionable driver mutation. For these patients, immunotherapy-based regimens remain first-line standard of care.

For nonsquamous metastatic NSCLC with a PD-L1 tumor proportion score (TPS) of 1% to 49%, the 2026 ASCO Living Guideline recommends:

• Pembrolizumab or cemiplimab added to platinum-doublet chemotherapy
• Alternatives: nivolumab-ipilimumab plus short-course chemotherapy, or durvalumab-tremelimumab plus chemotherapy

PD-L1 testing and driver-mutation testing work together. The combined results show whether a patient is best suited to targeted therapy, immunotherapy, or a combination approach.

Extending Precision Medicine to Earlier-Stage Disease

Targeted therapy and immunotherapy are increasingly moving from the metastatic setting into resectable and locally advanced disease.

• Unresectable stage III NSCLC: Updated NCCN guidelines list both durvalumab and osimertinib as consolidation options after chemoradiotherapy. Molecular testing guides which one is appropriate.
• Resected ALK-positive NSCLC: Adjuvant alectinib shows how molecular testing now shapes care after surgery, not only in metastatic treatment.

The next frontier in earlier-stage disease includes neoadjuvant and adjuvant mRNA vaccine combinations, discussed in detail below.

The Patient Journey: How Biomarker-Matched Therapies Are Sequenced

A representative treatment sequence in advanced NSCLC often follows this path:

1. Comprehensive biomarker testing (NGS, PD-L1, and possibly liquid biopsy)
2. First-line therapy matched to results: a targeted agent for driver-positive disease, or immunotherapy-based treatment for driver-negative disease
3. Monitoring for progression or resistance
4. Next-line options, which increasingly include antibody-drug conjugates

Three ADCs are now FDA-approved for biomarker-defined metastatic NSCLC:

ADC	Biomarker Target
Trastuzumab deruxtecan	HER2-altered
Telisotuzumab vedotin-tllv (Emrelis)	c-MET overexpression
Datopotamab deruxtecan (Datroway)	EGFR-mutated, after prior TKI and chemotherapy

Repeat biopsy or repeat molecular testing at progression is important. Tumors change under treatment pressure, and resistance mechanisms can reveal new actionable targets. Zidesamtinib after a prior ROS1 TKI is one example of how retesting can open a new treatment path.

Beyond Targeted Therapy: The Cell-and-Gene Therapy Frontier in NSCLC

As biomarker-matched drugs mature, a parallel wave of cell-and-gene therapy innovation is beginning to reach solid tumors such as NSCLC. Standard oncology overviews often leave this connection out.

For patients and caregivers following the next generation of treatments, this frontier matters. It is where many of the most promising clinical trial opportunities are emerging, particularly for people whose disease has progressed on standard therapies.

CAR-T and TCR-T Cell Therapy Moving Into Solid Tumors

CAR-T therapy has transformed the treatment of blood cancers, but solid tumors have been harder to address. In 2026, that changed. Satricabtagene autoleucel (satri-cel/CT041) became the first regulatory-approved CAR-T therapy for a solid tumor. It was approved in China in June 2026 for CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma, a proof of concept that engineered cell therapy can work in solid tumors.

Research in lung cancer is also underway. DLL3-targeted CAR-T (LB2102) is in trials for relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, an early signal of possible crossover toward NSCLC. Updates on CAR-T and TCR-T therapy presented at the 2026 ASCO Annual Meeting showed continued research momentum beyond hematologic cancers.

Tumor-Infiltrating Lymphocyte (TIL) Therapy

Lifileucel was the first FDA-approved cellular therapy for a solid tumor (melanoma) and became an NCCN-preferred second-line option in that setting in 2024. TIL therapy is now being explored in other solid tumors, including lung cancer. It may become a future option for NSCLC patients who progress on standard treatment.

TIL therapy differs from CAR-T in how it works:

• CAR-T engineers a patient’s T cells with a synthetic receptor aimed at a specific target.
• TIL therapy collects immune cells that have naturally infiltrated the patient’s tumor and already recognize it. These cells are expanded in large numbers in a lab and then reinfused.

mRNA Neoantigen Vaccines Entering NSCLC Trials

Personalized mRNA cancer vaccines train the immune system to recognize neoantigens, the unique mutations found in a patient’s own tumor.

Merck and Moderna’s V940/mRNA-4157 (intismeran autogene), combined with pembrolizumab, is being studied in:

• INTerpath-002: A Phase 3 trial for resected stage II, IIIA, or IIIB (N2) NSCLC
• INTerpath-009: A trial for patients who did not achieve a pathological complete response after neoadjuvant therapy, aimed at reducing the risk posed by residual disease

The program builds on positive Phase 3 recurrence-free survival data in melanoma, which gives early credibility to the NSCLC effort.

What the Expanding Pipeline Means for Patients Today

Several practical points stand out for patients and families:

• Ask about comprehensive biomarker and NGS testing before treatment begins. The results directly determine eligibility for the therapies described in this guide.
• Discuss both approved options and clinical trials, including cell-and-gene therapy studies, with the oncology care team. This is especially relevant after progression on standard therapy.
• Expect continued change. Pipeline agents such as zipalertinib, neladalkib, daraxonrasib, and ifinatamab deruxtecan (a B7-H3-targeted ADC under priority review in small cell lung cancer) suggest the treatment landscape will keep evolving quickly. Regular conversations with providers help patients stay informed about new options.
• Treatment remains individualized. Biomarker-matched and cellular therapies have meaningfully improved outcomes, but decisions should always be made together with a qualified oncology specialist.

Conclusion: A Biomarker-Driven Future for NSCLC Care

NSCLC treatment has moved from one-size-fits-all modalities to a biomarker-first model. EGFR, ALK, ROS1, HER2, MET, RET, KRAS, and NTRK each now have specific approved agents matched to the tumor’s molecular profile.

The 2026 approvals of zidesamtinib, sevabertinib, the expanded indication for zongertinib, and adjuvant alectinib show that progress is accelerating and treatment is becoming more personalized.

The next frontier, which includes CAR-T, TIL therapy, and mRNA neoantigen vaccines, extends precision oncology into cellular and regenerative medicine. The link between these fields is likely to shape the next decade of NSCLC care.

The rise in distant-stage survival from 2% to 10% is still far from enough, but it gives reason for cautious optimism grounded in steady scientific advances.

Next Steps: Staying Informed on Advanced and Emerging NSCLC Therapies

For patients, caregivers, and healthcare professionals, the most important first step toward a personalized treatment plan is comprehensive biomarker testing combined with specialist consultation.

Readers who want to learn more can explore further resources on biomarker testing, specific drug classes such as TKIs and antibody-drug conjugates, and clinical trial options for targeted and cell-based therapies. Adiamed encourages readers to connect with qualified oncology specialists to discuss their individual situation. Readers can also subscribe for ongoing updates on advances in precision oncology and regenerative, cell-based cancer therapies as the field continues to move forward.